References
- Fejzo MS, Trovik J, Grooten IJ et al. Nausea and vomiting of pregnancy
and hyperemesis gravidarum. Nat Rev Dis Primers 2019; 5: 1– 17.
- Einarson TR, Piwko C, Koren G. Quantifying the global rates of nausea
and vomiting of pregnancy: a meta analysis. J Popul Ther Clin
Pharmacol. 2013;20:e171- e183.
- Fiaschi L, Nelson- Piercy C, Gibson J, Szatkowski L, Tata LJ. Adverse
maternal and birthoutcomes in women admitted to hospital for
hyperemesis gravidarum: a population- based cohort study. Paediatr
Perinat Epidemiol. 2018;32:40- 51.
- Lowe SA, Armstrong G, Beech A et al. SOMANZ position paper on the
management of nausea and vomiting in pregnancy and hyperemesis
gravidarum. Aust N Z J Obstet Gynaecol 2020; 60: 34– 43.
- The Management of Nausea and Vomiting of Pregnancy and Hyperemesis
Gravidarum (Green-top Guideline No. 69) [Internet]. Royal College
of Obstetricians & Gynaecologists. [cited 2020 Feb 25]. Available
from: https://www.rcog.org.uk/en/guide lines -research-services/guide
lines/ gtg69/
- Fiaschi L, Nelson-Piercy C, Deb S, King R, Tata LJ. Clinical
management of nausea and vomiting in pregnancy and hyperemesis
gravidarum across primary and secondary care: a population-based
study. BJOG Int J Obstet Gynaecol. 2019; 126:1201-1211.
- Taylor LG, Bird ST, Sahin L, et al. Antiemetic use among pregnant
women in the United States: the escalating use of ondansetron.
Pharmacoepidemiol Drug Saf. 2017;26:592-596.
- Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No.
189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol.
2018;131:e15–30.
- Koren, G. (2014). Treating morning sickness in the United
States—Changes in prescribing are needed. American Journal of
Obstetrics and Gynecology, 2014,211(6), 602–606.https://doi.org/10.1016/j.ajog.2014.08.017
- Parker, S. E., Van Bennekom, C., Anderka, M.,Mitchell, A. A., &
National Birth Defects Prevention Study.(2018). Ondansetron for
treatment of nausea and vomiting of pregnancy and the risk of specific
birth defects. Obstetrics and Gynecology, 2018,132(2), 385–394.https://doi.org/10.1097/AOG.0000000000002679
- Taylor, L. G., Bird, S. T., Sahin, L., Tassinari, M. S., Greene,
P.,Reichman, M. E., … Toh, S. (2017). Antiemetic use among
pregnant women in the United States: The escalating use of
ondansetron. Pharmacoepidemiology and Drug Safety, 26(5),592–596.https://doi.org/10.1002/pds.4185
- Raymond, S. H. (2013). A survey of prescribing for the management of
nausea and vomiting in pregnancy in Australasia. The Australian & New
Zealand Journal of Obstetrics & Gynaecology,2013;53(4), 358–362.https://doi.org/10.1111/ajo.12045
- van Gelder MMHJ, Nordeng H. Antiemetic Prescription Fills in
Pregnancy: A Drug Utilization Study Among 762,437 Pregnancies in
Norway. Clin Epidemiol. 2021; 13:161-174. doi: 10.2147/CLEP.S287892.
eCollection 2021.
- Hurault-Delarue C, Araujo M, Vabre C, Benevent J, Damase-Michel C,
Lacroix I. What changes in prescription patterns of antiemetic
medications in pregnant women in France? Fundam Clin Pharmacol. 2021.
doi: 10.1111/fcp.12681. Online ahead of print.
- Ondansetron 4 mg film-coated tablets - Summary of Product
Characteristics (SmPC) - (emc) [Internet]. [cited 2020 Feb
25]. Available from: https://www.medic ines.org.uk/emc/produ
ct/5222/smpc#PREGN ANCY
- Damkier P, Kaplan YC, Shechtman S, Diav-Citrin O, Cassina M,
Weber-Schoendorfer C. Ondansetron in pregnancy revisited: Assessment
and pregnancy labelling by the European Medicines Agency (EMA) &
Pharmacovigilance Risk Assessment Committee (PRAC).Basic Clin
Pharmacol Toxicol. 2021;128(4):579-582. doi: 10.1111/bcpt.13541. Epub
2020 Dec 16.
- Melissa Lavecchia, Radha Chari, Sandra Campbell, Sue Ross. Ondansetron
in Pregnancy and the Risk of Congenital Malformations: A Systematic
Review. J Obstet Gynaecol Can. 2018 Jul;40(7):910-918. doi:
10.1016/j.jogc.2017.10.024.
- Yusuf Cem Kaplan, Jonathan Luke Richardson, Elif Keskin-Arslan, Hilal
Erol-Coskun, Debra Kennedy. Use of ondansetron during pregnancy and
the risk of major congenital malformations: A systematic review and
meta-analysis. Reprod Toxicol. 2019; 86:1-13. doi:
10.1016/j.reprotox.2019.03.001.
- Shaun D Carstairs. Ondansetron Use in Pregnancy and Birth Defects: A
Systematic Review. Obstet Gynecol. 2016;127(5):878-883. doi:
10.1097/AOG.0000000000001388.
- Cyndie Picot, Anick Berard, Guillaume Grenet, Emmanuelle Ripoche,
Michel Cucherat, Judith Cottin. Risk of malformation after ondansetron
in pregnancy: An updated systematic review and meta-analysis. Birth
Defects Res. 2020;112(13):996-1013. doi: 10.1002/bdr2.1705.
- Razan Sakran, Svetlana Shechtman, Judy Arnon, Orna Diav-Citrin.
Pregnancy outcome following in-utero exposure to ondansetron: A
prospective comparative observational study. Reprod Toxicol. 2021;
99:9-14. doi: 10.1016/j.reprotox.2020.11.005.
- Colin R Dormuth, Brandace Winquist, Anat Fisher, Fangyun Wu, Pauline
Reynier, Samy Suissa, Matthew Dahl, Zhihai Ma, Xinya Lu, Jianguo
Zhang, Colette B Raymond, Kristian B Filion, Robert W Platt, Carolina
Moriello, J Michael Paterson, Canadian Network for Observational Drug
Effect Studies (CNODES) Investigators. Comparison of Pregnancy
Outcomes of Patients Treated With Ondansetron vs Alternative
Antiemetic Medications in a Multinational, Population-Based Cohort.
JAMA Netw Open. 2021;4(4):e215329. doi:
10.1001/jamanetworkopen.2021.5329.
- Lara S Lemon, Lisa M Bodnar, William Garrard, Raman Venkataramanan,
Robert W Platt, Oscar C Marroquin, Steve N Caritis. Ondansetron use in
the first trimester of pregnancy and the risk of neonatal ventricular
septal defect. Int J Epidemiol. 2020;49(2):648-656. doi:
10.1093/ije/dyz255.
- Krista F Huybrechts, Sonia Hernandez-Diaz, Loreen Straub, Kathryn J
Gray, Yanmin Zhu, Helen Mogun 1, Brian T Bateman. Intravenous
Ondansetron in Pregnancy and Risk of Congenital Malformations. JAMA.
2020;323(4):372-374. doi: 10.1001/jama.2019.18587.
- Elizabeth A Suarez, Kim Boggess, Stephanie M Engel, Til Stürmer,
Jennifer L Lund, Michele Jonsson Funk. Ondansetron use in early
pregnancy and the risk of late pregnancy outcomes. Pharmacoepidemiol
Drug Saf. 2021;30(2):114-125. doi: 10.1002/pds.5151.
- The Ottawa Hospital, Wells GA, Shea B, O’Connell D, et al. The
Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non
randomised Studies in Meta-Analyses. 2001.
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
[Accessed 20 January 2018].
- Evidence Partners. Methodological resources.
https://www.evidencepartners.com/resources/methodological-resources/.
[Accessed 10 September 2019].
- Long Ge, Gordon Guyatt, Jinhui Tian, Bei Pan, Yaping Chang, Yajing
Chen, et al. Insomnia and risk of mortality from all-cause,
cardiovascular disease, and cancer: Systematic review and
meta-analysis of prospective cohort studies. Sleep Med Rev. 2019;
48:101215. doi: 10.1016/j.smrv.2019.101215.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
in meta-analyses. BMJ.2003;327:557e60.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation
test for publication bias. Biometrics.1994;50:1088e101.
- Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al.
Use of GRADE for assessment of evidence about prognosis: rating
confidence in estimates of event rates in broad categories of
patients. BMJ.2015;350:h870.
- D. Moher, A. Liberati, J. Tetzlaff, Altman DG for the PRISMA Group.
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. BMJ. 339 (2009) b2535.
- Marlena S Fejzo, Kimber W MacGibbon, Patrick M Mullin. Ondansetron in
pregnancy and risk of adverse fetal outcomes in the United States.
Reprod Toxicol. 2016; 62:87-91. doi: 10.1016/j.reprotox.2016.04.027.
- Şafak Özdemirci, F Akpınar, Bilge M, F Özdemirci,S Yılmaz,D
Esinler,İnci Kahyaoğlu. The Safety of Ondansetron and Chlorpromazine
for Hyperemesis Gravidarum in First Trimester Pregnancy. Gynecol
Obstet Reprod Med. 2014;20:81-84.
- Lyn Colvin, Andrew W Gill, Linda Slack-Smith, Fiona J Stanley, Carol
Bower. Off-label use of ondansetron in pregnancy in Western Australia.
Biomed Res Int. 2013:909860. doi: 10.1155/2013/909860.
- Anick Bérard, Odile Sheehy, Jessica Gorgui, Jin-Ping Zhao, Cristiano
Soares de Moura, Sasha Bernatsky. New evidence for concern over the
risk of birth defects from medications for nausea and vomitting of
pregnancy. J Clin Epidemiol. 2019; 116:39-48. doi:
10.1016/j.jclinepi.2019.07.014.
- Charlotte Asker, B Norstedt Wikner, Bengt Källén. Use of antiemetic
drugs during pregnancy in Sweden. Eur J Clin Pharmacol.
2005;61(12):899-906. doi: 10.1007/s00228-005-0055-1.
- Colin R Dormuth, Brandace Winquist, Anat Fisher, Fangyun Wu, Pauline
Reynier, Samy Suissa, et al. Comparison of Pregnancy Outcomes of
Patients Treated With Ondansetron vs Alternative Antiemetic
Medications in a Multinational, Population-Based Cohort. JAMA Netw
Open. 2021 Apr 1;4(4):e215329. doi: 10.1001/jamanetworkopen.2021.5329.
- Lara S Lemon, Lisa M Bodnar, William Garrard, Raman Venkataramanan,
Robert W Platt, Oscar C Marroquin, et al. Ondansetron use in the first
trimester of pregnancy and the risk of neonatal ventricular septal
defect. Int J Epidemiol. 2020;49(2):648-656. doi: 10.1093/ije/dyz255.
- Adrienne Einarson, Caroline Maltepe, Yvette Navioz, Deborah Kennedy,
Michael Paul Tan, Gideon Koren. The safety of ondansetron for nausea
and vomiting of pregnancy: a prospective comparative study. BJOG.
2004;111(9):940-3. doi: 10.1111/j.1471-0528.2004.00236.x.
- Krista F Huybrechts, Sonia Hernandez-Diaz, Loreen Straub, Kathryn J
Gray, Yanmin Zhu, Helen Mogun, et al. Intravenous Ondansetron in
Pregnancy and Risk of Congenital Malformations. JAMA.
2020;323(4):372-374. doi: 10.1001/jama.2019.18587.
- Elizabeth A Suarez, Kim Boggess, Stephanie M Engel, Til Stürmer,
Jennifer L Lund, Michele Jonsson Funk. Ondansetron use in early
pregnancy and the risk of late pregnancy outcomes. Pharmacoepidemiol
Drug Saf. 2021;30(2):114-125. doi: 10.1002/pds.5151.
- Björn Pasternak, Henrik Svanström, Anders Hviid. Ondansetron in
Pregnancy and Risk of Adverse Fetal Outcomes. N Engl J Med.
2013;368(9):814-23. doi: 10.1056/NEJMoa1211035.
- Martha M Werler, Mahsa M Yazdy, James R Kasser, Susan T Mahan, Robert
E Meyer, Marlene Anderka, et al. Medication use in pregnancy in
relation to the risk of isolated clubfoot in offspring. Am J
Epidemiol. 2014;180(1):86-93. doi: 10.1093/aje/kwu096.
- April Zambelli-Weiner, Christina Via, Matt Yuen, Daniel J Weiner,
Russell S Kirby. First trimester ondansetron exposure and risk of
structural birth defects. Reprod Toxicol. 2019; 83:14-20. doi:
10.1016/j.reprotox.2018.10.010.
- Razan Sakran, Svetlana Shechtman, Judy Arnon, Orna Diav-Citrin.
Pregnancy outcome following in-utero exposure to ondansetron: A
prospective comparative observational study. Reprod Toxicol. 2021
Jan;99:9-14. doi: 10.1016/j.reprotox.2020.11.005.
- Bengt Danielsson, Birgitta Norstedt Wikner, Bengt Källén. Use of
ondansetron during pregnancy and congenital malformations in the
infant. Reprod Toxicol. 2014; 50:134-7. doi:
10.1016/j.reprotox.2014.10.017.
- Samantha E Parker, Carla Van Bennekom, Marlene Anderka, Allen A
Mitchell. Ondansetron for Treatment of Nausea and Vomiting of
Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol. 2018
Aug;132(2):385-394. doi: 10.1097/AOG.0000000000002679.
- Michael Couse, Saba Syed. A Rise in Aspartate Transaminase and Alanine
Transaminase Associated With Ondansetron Administration in a Pregnant
Female. Cureus. 2020 Nov 18;12(11):e11540. doi: 10.7759/cureus.11540.
- Lara S Lemon, Hongfei Zhang, Mary F Hebert, Gary D Hankins, David M
Haas, Steve N Caritis. Ondansetron Exposure Changes in a Pregnant
Woman. Pharmacotherapy. 2016 Sep;36(9):e139-41. doi:
10.1002/phar.1796.
- E Ferreira, M Gillet, J Lelièvre, J-F Bussières. Ondansetron use
during pregnancy: a case series. J Popul. Ther Clin Pharmacol.
2012;19(1):e1-e10.
- Yusuf Cem Kaplan, Jonathan Luke Richardson, Elif Keskin-Arslan, Hilal
Erol-Coskun, Debra Kennedy. Use of ondansetron during pregnancy and
the risk of major congenital malformations: A systematic review and
meta-analysis. Reprod Toxicol. 2019;86:1-13. doi:
10.1016/j.reprotox.2019.03.001.
- Cyndie Picot, Anick Berard, Guillaume Grenet, Emmanuelle Ripoche,
Michel Cucherat, Judith Cottin. Risk of malformation after ondansetron
in pregnancy: An updated systematic review and meta-analysis. Birth
Defects Res. 2020;112(13):996-1013. doi: 10.1002/bdr2.1705.
- Melissa Lavecchia, Radha Chari, Sandra Campbell, Sue Ross. Ondansetron
in Pregnancy and the Risk of Congenital Malformations: A Systematic
Review. J Obstet Gynaecol Can. 2018;40(7):910-918. doi:
10.1016/j.jogc.2017.10.024.
- Shaun D Carstairs. Ondansetron Use in Pregnancy and Birth Defects: A
Systematic Review. Obstet Gynecol. 2016 May;127(5):878-883. doi:
10.1097/AOG.0000000000001388.
- Lyn Colvin, Andrew W Gill, Linda Slack-Smith, Fiona J Stanley, Carol
Bower. Off-label use of ondansetron in pregnancy in Western Australia.
Biomed Res Int. 2013;2013:909860. doi: 10.1155/2013/909860.
- L.G. Taylor, S.T. Bird, L. Sahin, M.S. Tassinari, P. Greene, M.E.
Reichman,S.E. Andrade, K. Haffenreffer, S. Toh, Antiemetic use among
pregnant women in the United States: the escalating use of
ondansetron, Pharmacoepidemiol. Drug Saf. 26(5) (2017) 592–596.
Table 1 Study characteristics